date:Jul 29, 2014
fety and suitability of other protein sources or new manufacturing technologies should be clinically evaluated prior to their use.
The safety and suitability of each specific infant and follow-on formula containing protein hydrolysates should also be established by clinical evaluation in the target population prior to use.
There is no need to add arachidonic acid, eicosapentaenoic acid, non-digestible oligosaccharides, probiotics or synbiotics, chromium, fluoride, taurine and nucleotides to inf